Synopsis:
Deep Diamond India Limited reports 2133% QoQ revenue growth and a 4117% QoQ net profit surge in Q2 FY26 results.
This penny stock under Rs. 10, engaged in manufacturing and wholesale trading of gold and diamond-studded jewellery, as well as loose diamonds and solitaires, and diversified into pharmaceuticals, jumped 16 percent after the company reported September quarterly results with a 2133 percent revenue growth and 4117 percent net profit growth in Q2 FY26.
With a market capitalization of Rs. 92.26 crores, the share of Deep Diamond India Limited has reached an intraday high of Rs. 6.70 per equity share, rising nearly 15.72 percent from its previous day’s close price of Rs. 5.79. Since then, the stock has retreated and is currently trading at Rs. 6.40 per equity share.
Q2 FY26 Result Walkthrough
Coming into the quarterly results of Deep Diamond India Limited, the company’s consolidated revenue from operations increased by 1,016.67 percent YOY, from Rs. 0.30 crore in Q2 FY25 to Rs. 3.35 crore in Q2 FY26, and grew by 2,133.33 percent QoQ from Rs. 0.15 crore in Q1 FY26.
In Q2 FY26, Deep Diamond India Limited’s consolidated net profit increased by 1,231.58 percent YOY, reaching Rs. 2.53 crore compared to Rs. 0.19 crore during the same period last year. As compared to Q1 FY26, the net profit has increased by 4,116.67 percent, from Rs. 0.06 crore.
Deep Diamond India Limited generated 100 percent of its revenue from pharmaceutical business sales in Q2 FY26. The basic earnings per share increased by 1,225 percent and stood at Rs. 0.53 as against Rs. 0.04 recorded in the same quarter in the previous year, 2025.
In terms of return ratios, the company’s ROCE and ROE stand at 5.37 percent and 4.11 percent, respectively. Deep Diamond India Limited has an earnings per share (EPS) of Rs. 0.09, and its debt-to-equity ratio is 0.03x.
Company Overview
Deep Diamond India Limited was incorporated in 1994 and is a publicly listed company primarily engaged in the manufacturing and trading of gold and diamond-studded jewellery, along with rough and polished diamonds.
The company has recently diversified its operations by entering the pharmaceutical sector, offering consultancy services, and developing prescription drugs, over-the-counter medicines, and medical devices since the financial year 2022–23.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
